EMCURE PHARMACEUTICALS L EMCURE.NS · Stock Open EMCURE PHARMACEUTICALS L in new tab
Analyst price targets
Recent rating changes, newest first
EMCURE PHARMACEUTICALS L Analysis (EMCURE.NS)
Is EMCURE PHARMACEUTICALS L a good investment? EMCURE PHARMACEUTICALS L (EMCURE.NS) is currently trading at 1868.60 INR. Market analysts have a consensus price target of 2229.38 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 34.37. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: EMCURE PHARMACEUTICALS L is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is 77.72.
For income investors, EMCURE PHARMACEUTICALS L pays a dividend yield of 0.19%. With a payout ratio of 6%, the dividend appears sustainable.
Investor FAQ
Does EMCURE PHARMACEUTICALS L pay a dividend?
Yes, it pays an annual dividend of 3.60 INR (0.19% yield).
What asset class is EMCURE PHARMACEUTICALS L?
EMCURE PHARMACEUTICALS L is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 53.35.
Company Profile
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients, respiratory, HIV antivirals, Metabolics, gastro, anti-diabetic, neuro, derma, and mRNA vaccine. It provides its products under Orofer-Xt, Zostum, Bevon, Amaryl M, Orofer Fcm, Maxtra, Clexane, Metpure-Xl, Amaryl, Spegra, Feronia-Xt, Cardace, Pause, Lornit, Targocid, Orofer-S, Lasilactone, Gros, Orofer-Xt Liq, And Tenectase brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
| Year | Total Dividends |
|---|---|
| ▸2026 |
3.60 INR
|
| Oct. 19, 2026 | 3.6000 |
| ▸2025 |
3.00 INR
|
| Sept. 8, 2025 | 3.0000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| EMCURE PHARMACEUTICALS L | Oct 19, 2026 | Upcoming | 3.6 INR |
Community Discussion